Get to know our clinical trials
Clinical trial of TSR-022, an anti-TIM-3 monoclonal antibody, in patients with advanced solid tumors (AMBER)
THIS IS A RESEARCH STUDY TO EVALUATE AN INVESTIGATIONAL NEW DRUG CALLED TSR-022. AN INVESTIGATIONAL DRUG IS A DRUG THAT HAS NOT BEEN AUTHORIZED BY ANY OF THE HEALTH AUTHORITIES, INCLUDING THE SPANISH AGENCY OF MEDICINES AND HEALTH PRODUCTS (AEMPS), AND IS NOT AVAILABLE FOR SALE OR BY PRESCRIPTION.
Technical Summary
- PHASE I DOSE-ESCALATION AND COHORT EXTENSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS (AMBER)
- Code EudraCT: 2018-002143-29
- Protocol number: 4020-01-001
- Promoter: TESARO Inc.
- Molecule/Drug: TSR-022
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.